Company profile

Hilo

Remote Patient Monitoring & Wearables

Company profile

About Hilo

Hilo is a subscription-based remote patient monitoring company that provides continuous, cuffless blood pressure monitoring through a clinically validated wearable system. The company's solution combines three core components: the Hilo Band (a medical-grade wearable for continuous monitoring), the Hilo Cuff (for periodic calibration), and the Hilo App (for insights and reporting). Unlike traditional blood pressure cuffs that capture single moments, Hilo automatically measures blood pressure approximately 25 times per day throughout day and night, revealing patterns linked to sleep, stress, movement, and recovery. The technology is powered by Aktiia's platform, built on over 20 years of research and used by more than 120,000 people worldwide. Hilo uses photoplethysmography (PPG) and pulse wave analysis (PWA) to estimate blood pressure from optical wrist data. The system is CE-marked as a Class IIa medical device under EU MDR and validated according to ISO 81060-2 international standards. Clinical studies have demonstrated that users with high or very high blood pressure were able to reduce systolic readings by up to 7 mmHg after six months of monitoring. The Hilo App provides weekly and monthly blood pressure averages, trend analysis, time-in-target-range metrics, and doctor-ready reports. The system integrates with Apple Health and Health Connect, and includes sleep duration and activity tracking to help users understand lifestyle factors affecting cardiovascular health. Hilo primarily serves consumers managing hypertension and healthcare providers seeking continuous blood pressure data for their patients.

Company description Hilo official website

Primary marketRemote Patient Monitoring & Wearables
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at Hilo?

Claim this profile to manage Company information and connect with the Health AI Central audience.

Claim this listing

01 · Operating footprint

Where the Company operates

Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.

Clinical focus

  • Cardiovascular health monitoring
  • High blood pressure
  • Hypertension

Who it serves

  • Consumers
  • Healthcare providers
  • Patients with hypertension

Deployment & integration

Cloud Saas · Embedded · Hybrid deployment with recorded integration context.

Recorded integration context: Apple Health, Health Connect.

Geographic context

MarketsEuropean Union · Germany · United Kingdom
Company sourceOfficial website

Company milestones

Platform expansion

Named Best blood pressure monitoring solution in Europe 2025. Over 120,000 users worldwide using Aktiia-powered technology. 4.7 rating with 1.9k App Store reviews.

Partnerships

Recorded partners

  • Aktiia (technology platform provider)
  • CSEM SA Switzerland (patent licensor)
  • iRhythm (Dr. Jay Shah endorsement)

02 · Flagship portfolio

Products, workflows, and platform capabilities

Selected source-backed Company products and the available commercial context.

Hilo App

View blood pressure trends, personalized insights and doctor-ready reports

Software · Cloud SaaSCompany source

Hilo Band

Medical-grade wearable for continuous blood pressure monitoring

Device · EmbeddedCompany source

Hilo Blood Pressure Monitoring System

Clinically certified cuffless and continuous blood pressure monitoring solution

Device · HybridCompany source

Hilo Cuff

Upper-arm cuff for initial and periodic calibration

Device · EmbeddedCompany source

03 · Research intelligence

Research Intelligence evidence

Publications, preprints, clinical validation, and regulatory records in Evidence Position order.

Evidence position

Publications, clinical validation, and regulatory records connected to this Company appear here.

Research

Publications & preprints

Shifting drivers and predictable corridors of an illegal wildlife trade network.

Proceedings of the National Academy of Sciences of the United States of America · Sep 8, 2026

Machine learning-enabled chemical ecology for integrated pest management: from volatiles to field applications.

Journal of insect science (Online) · Sep 1, 2026

Persistent behavioral, biological, and physiological sequelae in active-duty treatment-seeking U.S. special operations forces personnel: a cross-sectional study.

Lancet regional health. Americas · Sep 1, 2026

Considerations for Offering an Extended Online Doctor of Pharmacy Program.

American journal of pharmaceutical education · Aug 24, 2026

Identifying wastewater pollution hotspots in coastal Hawaiian waters with high freshwater inputs.

Marine pollution bulletin · Aug 20, 2026

Discovery of Monoterpenoid Indole Alkaloids Targeting CCN1 to Suppress Autophagy for the Treatment of Hypoxic Kidney Injury.

Journal of medicinal chemistry · Aug 18, 2026

Clinical validation

Clinical-trial records

Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas

NCT03984448 · Mentioned · ACTIVE NOT RECRUITING

Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia

NCT03737981 · Mentioned · ACTIVE NOT RECRUITING

Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia

NCT03701282 · Mentioned · ACTIVE NOT RECRUITING

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

NCT03150693 · Mentioned · RECRUITING

T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial

NCT04457596 · Mentioned · ACTIVE NOT RECRUITING

Association of Thoraco-mediastinal Radiotherapy With Maintenance Immunotherapy Treatment With Atezolizumab

NCT06771518 · Mentioned · RECRUITING

Regulatory

Regulatory records

No linked records are currently available.

04 · Company-reported outcomes

Outcomes and case studies

Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.

Systolic blood pressure reduction up to 7 mmHg

After 6 months of monitoring in users with high or very high blood pressure

Approximately 25 automatic measurements per day

Continuous monitoring without user intervention

Mean measurement error ±5 mmHg

For both systolic and diastolic readings per ISO 81060-2 validation

Hilo users with high or very high blood pressure

Reduction of high blood pressure through continuous monitoring

Up to 7 mmHg reduction in systolic blood pressure after 6 months of monitoring

05 · Leadership

Leadership team

Leadership profiles and professional links from the current Company record.

06 · Company updates

Updates from Hilo

Recent articles published on Hilo's official website.

07 · HAIC coverage

Coverage and analysis

Health AI Central reporting that mentions this Company.

No HAIC coverage is currently linked to this Company.

08 · Official presence

Company sources and channels

Curated official destinations from the active Company record.

09 · Market pathway

Additional Companies in this Market

Other active Companies in the same market, selected alphabetically from the HAIC directory.

Market context

Remote Patient Monitoring & Wearables

Companies providing AI-powered remote patient monitoring solutions, wearable health devices with AI analytics, continuous health tracking, or platforms that monitor patients outside clinical settings. Includes general wellness wearables with AI coaching, respiratory monitoring devices, and connected health platforms that aggregate and analyze physiological data from sensors.

Explore the full market directory or compare this Company with additional active profiles.

View all Companies in this market

10 · Pro research

Coming soon

Expanded Company research is in development.

Health AI Central Pro · Coming Soon

Deeper Company research is coming soon.

Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.

ResearchEvidence analysis

Linked research, clinical, and regulatory source pathways.

CompanyTechnical context

Expanded product, deployment, integration, and partnership research.

MethodSource & review record

Record-level provenance and review context.

Coming Soon